Antonio Steardo

MSc CChem AMRSC RPharmS, Pharmacist Chemist and Pharmacologist, Italy

Abstract

The organ function deterioration due to oxygen delivery decrease can compromise several organ functions. For instance, hypoxic brain damage due to severe COVID-19 can be encountered in neuroimaging findings. Acute hypoxemia causes hypoxic-ischemic encephalopathy. Instead, prolonged hypoxia may induce demyelination or produce white matter microhemorrhages, and oligodendroglia cell injury. It also causes the disruption of the blood-brain barrier leading to leaky capillaries disruption due to microhemorrhagesFurthermore, silent hypoxemia due to SARS-cov-2 infection is common. Preventive measures such as premature intubation can prevent the risk of sudden respiratory complications. Therefore, respiratory arrest during emergency intubation must be avoided to pre-treat silent and acute hypoxia in patients. It should also prevent Health Care workers’ infection. Even though careful respiratory status identifies the criteria of intubation for severe hypoxemia based on medical evidence, evaluation of its management and its results on general organ function deterioration due to oxygen delivery. Although SARS-cov-2 infection is now progressive in its studies, it is necessary for an appropriate risk/benefit evaluation for the improvement of patient treatment and management.

Biography:

Doctor Antonio Steardo specialized in Pharmacology and graduated in Pharmacy and Pharmaceutical Chemistry. He has now gained years of experience since 2002 in the pharmaceutical products trade sector as he could have been behind the counter of the Steardo pharmacy from an early age. Already in elementary school, their curiosity for chemistry manifests itself during his games and continues lectures at the department of science at the University of Salerno. Therefore, during the cycle of studies, he prefers biochemistry and biochemistry of drug action, graduating in July 2007 with a thesis on the functioning of the endocannabinoid system on Alzheimer’s disease in pharmacology. Following the beginning of his pharmaceutical chemistry studies, he stopped for a competition as a postgraduate in pharmacology at the University of Rome La Sapienza in July 2014. Expecting constant improvement as a professional update, he enrolled in the continuing professional training department at the University of Oxford to follow courses in Experimental and Translation Therapy and Medical Research. His desire to improve leads him to attend international conferences and seminars.